Main Conference Day 3 - CET (Central European Time, GMT+01:00)
Main Conference Day 3
- CET (Central European Time, GMT+01:00)
07:30 - 08:0030 mins
Morning Spotlight Presentation
Therapeutic Nucleic Acids - Advanced Solutions for Analytics and Downstream Processing
- Patrick Endres - Manager - Product Management EMEA, Tosoh Bioscience GmbH
08:00 - 08:055 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairperson’s Remarks: Antibody-Oligonucleotide Conjugates (AOCs): Discovery, Delivery & CMC
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
08:00 - 08:055 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairperson’s Remarks: Regulatory CMC Strategies for Oligonucleotides
- Daniel Waschke, PhD - Associate Regulatory Program Director, F. Hoffmann-La Roche Ltd.
08:00 - 08:055 mins
Peptide Discovery to CMC
Chairman’s Remarks: New Developments in Peptide Synthesis and Manufacturing
- John Lopez, PhD - Associate Director Science & Technology, Novartis
08:05 - 08:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Interferon Gamma Enhances the Potency of Receptor Targeted siRNA Conjugates by Promoting Endosomal Escape
- Katherine Palozola, PhD - Senior Principal Investigator, Biology, Aro Biotherapeutics
08:05 - 08:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
EMA Draft Guideline on the Development and Manufacture of Oligonucleotides
- René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
08:05 - 08:3530 mins
Peptide Discovery to CMC
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
- Martin Kenworthy, PhD - Principal Scientist, Chemical Development, AstraZeneca
08:35 - 09:0530 mins
Oligonucleotide Discovery, Preclinical and Clinical
GlycoConnect® Antibody-Oligonucleotide Conjugates for Sustained Muscle Improvement in Mouse Model of Duchenne Muscular Dystrophy (DMD)
- Floris van Delft, PhD - Head of R&D, Synaffix/Lonza
08:35 - 09:0530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Industry Comments on EMA Oligo Guideline
- Inaam Bouchouika - Technical Regulatory Manager, Roche Pharmaceuticals Middle East FZCO
08:35 - 09:0530 mins
Peptide Discovery to CMC
The Challenge of Substituting PFAS in the Final Global Deprotection Step
- Fernando Albericio, PhD - Research Professor, School of Chemistry, University of Kwazulu-Natal
09:05 - 09:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
CMC Considerations Around Denali’s Oligonucleotide Transport Vehicle (OTV) Platform and Our Antibody ASO Conjugates
- Firoz Antia, PhD - Vice President, Oligonucleotide & Small Molecule CMC, Denali Therapeutics
09:05 - 09:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Fluidized Bed Reactor Strategy to Solid Phase Synthesis from Regulatory Perspective
- Jessica Zelinski - Senior Engineer, Process Development, Eli Lilly and Company
09:05 - 09:3530 mins
Peptide Discovery to CMC
Optimizing Industrial Solid-Phase Peptide Synthesis: Integration of Raman Spectroscopy as Process Analytical Technology
- Michael Stager, PhD - Senior Development Engineer, Corden Pharma Colorado
09:35 - 10:1540 mins
Networking Refreshment Break in Poster and Exhibit Hall
10:15 - 10:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Optimizing Oligo Protein Conjugates with Chemistry-Driven Solutions for Enhanced Properties and Scale-Up
- Naresh Jain, PhD - CEO, NJ Bio
10:15 - 10:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Evolving Regulatory Expectation for Synthetic Oligonucleotides
- Dominik Altevogt, PhD - Director Regulatory Affairs CMC, F.Hoffmann-La Roche Ltd
10:15 - 10:4530 mins
Peptide Discovery to CMC
Future Challenge and Opportunities in Peptide Synthesis and Peptide Radioligands
- John Lopez, PhD - Associate Director Science & Technology, Novartis
10:45 - 11:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Delivering on the RNA Revolution
- Seb Caille, PhD - Senior Director, Avidity Biosciences
10:45 - 11:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Practical Application of Platform Approaches for Oligonucleotides
- Jennifer Franklin - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
10:45 - 11:1530 mins
Peptide Discovery to CMC
Green TAPS - Where to Put Which Tag in Tag-Assisted-Peptide-Synthesis
- Thomas Bruckdorfer, PhD - CSO & VP Business Development, Iris Biotech GmbH
11:15 - 11:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Antibody-oligo-SPT Conjugates in Preclinical Patient Cells and Animal Models
- Ruben Postel - CSO & Scientific Founder, Sapreme Technologies
11:15 - 11:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Oligonucleotide Odyssey: Regulatory CMC Insights from Recent Global Filings
- Karin Grosch - CMC Regulatory Affairs Director, AstraZeneca
11:15 - 11:4530 mins
Peptide Discovery to CMC
Scaling New Heights: Efficient Liquid-phase Based Peptide Synthesis in Large-scale
- Daisuke Takahashi, PhD - Executive Specialist, Ajinomoto Co. Inc.
11:45 - 11:505 mins
Transition to Spotlight Presentations
Spotlight Presentations
11:50 - 12:2030 mins
Spotlight Presentation 1
Unlocking the Potential: Challenges and Opportunities in Oral Delivery of Peptides, Oligonucleotides
- Christoph Schmoelzer - Head of Product Management, Advanced Therapies, Thermo Fisher Scientific
11:50 - 12:2030 mins
Spotlight Presentation 2
Enzymatic Assembly of Ultra-long gRNA at Gram Scale
- Jacob Guo, PhD - Director of Nucleic Acid R&D Platform, GenScript
11:50 - 12:2030 mins
Spotlight Presentation 3
Cytiva Scientific Briefing
12:20 - 13:2565 mins
Networking Luncheon in Poster and Exhibit Hall
13:25 - 13:5530 mins
Spotlight Presentation 1
Ajinomoto Scientific Briefing
13:25 - 13:5530 mins
Spotlight Presentation 3
Waters/Micromass Scientific Briefing
13:55 - 14:005 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman’s Remarks: Leveraging Advances in mRNA and Genome Editing
13:55 - 14:005 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairman’s Remarks: Oligonucleotide and mRNA Manufacturing & Process Development
13:55 - 14:005 mins
Peptide Discovery to CMC
Chairman’s Remarks: Emerging Approaches in Peptide Process Development and Manufacturing
14:00 - 14:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Development of ETH47 for the Treatment of Asthma
- Thomas Langenickel, MD, PhD - Chief Medical Officer, Ethris GmbH
14:00 - 14:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Agilent Oligonucleotide Manufacturing/CMC Presentation
14:00 - 14:3030 mins
Peptide Discovery to CMC
Assessing the Risks and Stability of Nitroso-Drug Substance-Related Impurities in Synthetic Peptide API's
- Niall McLoughlin, PhD - Senior Scientist, Process Chemistry & Catalysis, F. Hoffmann-La Roche AG
14:30 - 15:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
CureVac's Tailored LNP Platforms for Prophylactic and Therapeutic mRNA Vaccine
- Vusala Ibrahimova, Ph.D. - Research Scientist, CureVac SE
14:30 - 15:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Microbial Control Strategy to Support Oligonucleotide Solution APIs
- Victor Goetz, PhD - Executive Director, TS/MS New Modalities, Eli Lilly and Company
14:30 - 15:0030 mins
Peptide Discovery to CMC
Modernizing SPPS for CMC Excellence: Yield, Control, and Sustainability
- Hanson Chang - VP/GM, Engineering & Instrumentation, CSBio
15:00 - 15:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
The Use of a New All-RNA Gene Editing Platform to Engineer CAR-T Cells In Vivo
- Alberto De Iaco, PhD - Director, Platform Development - Gene and Cell Therapy, Tessera Therapeutics
15:00 - 15:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Streamlining Oligonucleotide Manufacture: Improving Efficiency and Sustainability via Implementation of Single Chromatography
- Muhid Bin Shahid, PhD - Senior Process Engineer, Chemical Development, AstraZeneca
15:00 - 15:3030 mins
Peptide Discovery to CMC
Peptides - A Trending Modality with Unlimited Potential
- Gildas Deniau, PhD - Principal Scientist, Chemical Process R&D, Johnson & Johnson Innovative Medicine
- Pius Baur - Scientific Director, Johnson & Johnson Innovative Medicine
15:30 - 16:0030 mins
Networking Refreshment Break in Poster and Exhibit Hall
16:00 - 16:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Advancing ADAR RNA Base Editing Technology for Broad Applicability in Precision Medicines
- Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
16:00 - 16:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Developing Oligonucleotide Purification Processes with Continuous Twin-column Chromatography (MCSGP)
- Bertrand Guélat, PhD - Senior Expert Science & Technology, Novartis
16:00 - 16:3030 mins
Peptide Discovery to CMC
Developing Tag-Assisted Peptide Synthesis for Manufacturing Scale
- Henrik Johansson Castro, PhD - Senior Development Scientist, Novo Nordisk
16:30 - 17:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
AI-Guided Metagenomic Discovery of Compact CRISPR Systems for In Vivo Therapeutic Genome Editing
- Christopher Brown, PhD - Vice President of Discovery, Metagenomi
16:30 - 17:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
A Design of Experiment Approach to Improve the Quality of mRNA Vaccines
- Sergio Linares Fernandez, PhD - Principal Scientist, Sanofi
16:30 - 17:0030 mins
Peptide Discovery to CMC
Late Breaking Presentation
17:00 - 17:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Building a Best-in-class RNA Editing Platform for the Treatment of Genetic Diseases
- Sriram Sathy, Ph.D. - Chief Scientific Officer, AIRNA
17:00 - 17:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Biofoundry-in-a-Box™: By-Design mRNA Manufacturing in a Box
- Harris Makatsoris - Academics Professor of Sustainable Manufacturing Systems, King's College London
17:00 - 17:3030 mins
Peptide Discovery to CMC
Late Breaking Presentation
17:30 - 17:355 mins
Close of Conference
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.